Michael Lawrence, M.D. Allergy & Immunology - Allergy Medicare: Accepting Medicare Assignments Practice Location: 35 Pearl St, Suite 300, Brockton, MA 02301 Phone: 508-584-6300 Fax: 508-580-4664 |
Mark T Claus, M.D. Allergy & Immunology - Allergy Medicare: Accepting Medicare Assignments Practice Location: 35 Pearl St, Suite 300, Brockton, MA 02301 Phone: 508-584-6300 Fax: 508-580-4664 |
News Archive
Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that the US Food and Drug Administration has accepted its Investigational New Drug application to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease. The Company plans to initiate the Phase 3 study in the US in H1 2014 and positive data would be the cornerstone of a subsequent NDA submission.
Today, Citizens for Responsibility and Ethics in Washington (CREW) sent a letter to MSNBC President Phil Griffin asking that MSNBC stop airing an ad sponsored by the U.S. Citizens Association. The ad, which ran at least once on August 27, 2009, during Morning Joe, violates Federal Communications Commission (FCC) regulations and NBC's advertising policy.
CMU's Jeffrey O. Hollinger, director of the center, and Professor Krzysztof Matyjaszewski have received a three-year, $2.9 million U.S. Department of Defense research grant to develop a therapy that would aid amputees, specifically wounded soldiers. The therapy aims to prevent bone nodules from forming in the muscle at the site of amputation, a painful condition that makes it difficult for amputees to wear limb prostheses.
In a study published in the current issue of Psychotherapy and Psychosomatics the effects of psychotherapy on cortisol, the most important stress hormone, are examined.
› Verified 3 days ago